Revenue
No reported data
Hemab Therapeutics Holdings, Inc. (COAG)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $59.6M | $41.4M |
| Operating income | −$70.1M | −$50.4M |
| EBITDAderived | −$69.8M | −$50.1M |
| Net income | −$63.9M | −$48.7M |
| Diluted EPSper diluted share | -$67.56 | -$51.49 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | BuyCommon Stock · indirect | 61.5K | $24.98 | $1.54M | 6.44M |
| Jun 15, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | BuyCommon Stock · indirect | 6.1K | $24.89 | $153.0K | 6.38M |
| May 20, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | BuyCommon Stock · indirect | 996 | $24.94 | $24.8K | 6.38M |
| May 19, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +3TenPercentOwner | BuyCommon Stock · indirect | 3.8K | $24.97 | $94.9K | 6.38M |
| May 12, 2026Form 4 | Kolchinsky Peter +3TenPercentOwner | BuyCommon Stock · indirect | 6.4K | $24.90 | $159.0K | 6.37M |